--- a
+++ b/clusters/9knumclustersv2/clust_1068.txt
@@ -0,0 +1,35 @@
+Patients must not have received prior cisplatin or poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors; prior carboplatin in the adjuvant/neoadjuvant setting and prior treatment with iniparib is allowed, if completed more than  months prior to study entry
+Part , Cohort , Patients must have received ?  prior treatment regimens for ovarian cancer including a platinum-based regimen. Patients whose OC harbors a mutation in breast cancer gene (BRCA), either germline or somatic, must have been previously treated with a poly(ADP ribose) polymerase (PARP) inhibitor, or be considered unwilling or ineligible for treatment with a PARP inhibitor
+Patients previously treated with a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor may be enrolled provided:\r\n* PARP inhibitor was not the most recent treatment\r\n* PARP inhibitor treatment was discontinued >  months before the first planned dose of rucaparib
+Patients who have received a prior inhibitor of vascular endothelial growth factor (VEGF) signaling inhibitor, or a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor administered
+Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
+Prior treatment with poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors (example (e.g.), olaparib, veliparib [ABT-])
+Prior treatment with a poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
+Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
+Any previous treatment with poly-adenosine diphosphate ribose polymerase (PARP) inhibitor, including olaparib
+Received any prior poly ADP-ribose polymerase inhibitor (PARPi) treatment
+Patients who are taking or anticipate taking any maintenance therapy while actively being treated on protocol or while being followed on protocol will be excluded; an example of this would be maintenance therapy with a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor such as olaparib
+TREATMENT: Patients with ovarian cancer and breast cancer gene (BRCA) mutations must have received specific poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy; if these patients have other mutations of interest, they will be eligible to receive agents based on that mutation
+Prior poly ADP ribose polymerase (PARP) inhibitor therapy is allowed; patients with ovarian cancer and a BRCA mutation should have had prior treatment with olaparib per guidelines for standard of care treatment
+Patients who have received prior therapy with a temozolomide-based regimen are eligible; Note: patients who have progressed on a poly adenosine diphosphate ribose polymerase (PARP) inhibitor and temozolomide regimen are not eligible for Part A of the study
+Participants with prior exposure to poly-ADP-ribose polymerase (PARP) inhibitors.
+Prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor
+Patients must have discontinued all biologic therapy at least  days prior to registration; prior poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors are allowed in the metastatic setting; prior PARP inhibitors in the neo/adjuvant setting are permissible; all toxicities related to prior biologic therapy must have resolved to CTCAE v. grade  or lower
+Participant has received prior therapy with a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.
+Previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.
+Prior treatment with poly ADP ribose polymerase (PARP) inhibitors (eg., olaparib, ABT-)
+Known allergic reaction or poor tolerability to poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors, carboplatin, or paclitaxel
+Patients may not have received prior poly ADP ribose polymerase (PARP) inhibitors
+Participants may not have had prior use of poly ADP ribose polymerase (PARP) inhibitors; patients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, or sorafenib
+All patients with ovarian, fallopian tube or primary peritoneal cancer and ovarian carcinosarcoma must have recurrent disease, and only one prior line of chemotherapy that must have been platinum-based chemotherapy for the management of primary disease; this initial platinum-based treatment may have included intraperitoneal therapy, consolidation/maintenance and/or biologic/targeted agents (e.g., bevacizumab, poly adenosine diphosphate [ADP] ribose polymerase [PARP] inhibitor) as part of first-line treatment
+Patients may have unlimited prior chemotherapeutic regimens for management of recurrent locally advanced endometrial carcinoma, recurrent ovarian carcinoma, or metastatic triple negative breast cancer; treatment as frontline therapy for metastatic disease is acceptable; patients who have received prior poly (adenosine diphosphate [ADP]-ribose) polymerase  (PARP) inhibitors, MTOR inhibitors, and/or AKT inhibitors are allowed to participate; patients may have progressed on prior PARP inhibitor, MTOR inhibitor, or AKT inhibitor but they may not have discontinued drug for toxicity
+Patients who have received prior bevacizumab (or any other vascular endothelial growth factor [VEGF] targeted agent) or prior poly ADP ribose polymerase (PARP) inhibitor
+Prior treatment of breast cancer with temozolomide, a platinum agent, or a Poly (ADP ribose) Polymerase (PARP) inhibitor.
+Prior treatment with poly ADP ribose polymerase (PARP) inhibitors (e.g., olaparib, ABT-).
+Prior exposure to PARP (poly ADP-ribose polymerase) inhibitors
+Prior treatment with a known poly (ADP-ribose) polymerase (PARP) inhibitor
+Prior treatment with a known poly (ADP-ribose) polymerases (PARP) inhibitor
+Prior treatment with talazoparib or a poly(adenosine diphosphate [ADP]-ribosyl)ation (PARP)/ inhibitor; prior treatment with other agents that inhibit deoxyribonucleic acid (DNA) repair (i.e. WEE homolog [S. pombe] [WEE] inhibitors, ataxia telangiectasia mutated [ATM] inhibitors), is allowed; if there are any questions, please contact the study's principal investigator
+Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade  or  AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor.
+Prior allergic reaction or severe intolerance (meeting the criteria for a serious adverse event, a grade  or  AE, or permanent treatment discontinuation) to a poly ADP ribose polymerase (PARP) inhibitor.
+Treatment with a prior investigational agent within  days of planned instillation of NanoPac, with the exception of subjects participating in poly (ADP-ribose) polymerase (PARP) inhibitor trials. These subjects must discontinue the investigational agent prior to surgery